These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 25286347

  • 1. In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.
    Marsouvanidis PJ, Melis M, de Blois E, Breeman WA, Krenning EP, Maina T, Nock BA, de Jong M.
    Cancer Biother Radiopharm; 2014 Nov; 29(9):359-67. PubMed ID: 25286347
    [Abstract] [Full Text] [Related]

  • 2. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
    Maina T, Kaloudi A, Valverde IE, Mindt TL, Nock BA.
    Nucl Med Biol; 2017 Sep; 52():57-62. PubMed ID: 28636973
    [Abstract] [Full Text] [Related]

  • 3. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H, Desai P, Koike Y, Houghton J, Carlin S, Tandon N, Touijer K, Weber WA.
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [Abstract] [Full Text] [Related]

  • 4. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
    Koumarianou E, Mikołajczak R, Pawlak D, Zikos X, Bouziotis P, Garnuszek P, Karczmarczyk U, Maurin M, Archimandritis SC.
    Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
    [Abstract] [Full Text] [Related]

  • 5. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee SY, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
    [Abstract] [Full Text] [Related]

  • 6. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.
    Mitran B, Rinne SS, Konijnenberg MW, Maina T, Nock BA, Altai M, Vorobyeva A, Larhed M, Tolmachev V, de Jong M, Rosenström U, Orlova A.
    Int J Cancer; 2019 Dec 15; 145(12):3347-3358. PubMed ID: 31077356
    [Abstract] [Full Text] [Related]

  • 7. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee Sy, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Feb 15; 42(2):131-6. PubMed ID: 25457455
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F.
    Nucl Med Biol; 2013 Nov 15; 40(8):1025-34. PubMed ID: 23969085
    [Abstract] [Full Text] [Related]

  • 9. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.
    J Nucl Med; 2017 Jan 15; 58(1):75-80. PubMed ID: 27493272
    [Abstract] [Full Text] [Related]

  • 10. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting.
    Nock BA, Maina T, Krenning EP, de Jong M.
    J Nucl Med; 2014 Jan 15; 55(1):121-7. PubMed ID: 24287321
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
    Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE.
    J Nucl Med; 2009 Dec 15; 50(12):2017-24. PubMed ID: 19910427
    [Abstract] [Full Text] [Related]

  • 14. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Breeman WA, Krenning EP, de Jong M.
    Int J Cancer; 2010 Jun 15; 126(12):2826-34. PubMed ID: 19876914
    [Abstract] [Full Text] [Related]

  • 15. Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
    Lymperis E, Kaloudi A, Sallegger W, Bakker IL, Krenning EP, de Jong M, Maina T, Nock BA.
    Bioconjug Chem; 2018 May 16; 29(5):1774-1784. PubMed ID: 29664606
    [Abstract] [Full Text] [Related]

  • 16. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
    Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, Maecke HR.
    Eur J Nucl Med Mol Imaging; 2007 Aug 16; 34(8):1198-208. PubMed ID: 17262215
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
    García Garayoa E, Schweinsberg C, Maes V, Rüegg D, Blanc A, Bläuenstein P, Tourwé DA, Beck-Sickinger AG, Schubiger PA.
    Q J Nucl Med Mol Imaging; 2007 Mar 16; 51(1):42-50. PubMed ID: 17372572
    [Abstract] [Full Text] [Related]

  • 20. Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon.
    Kaloudi A, Nock BA, Lymperis E, Krenning EP, de Jong M, Maina T.
    Cancer Biother Radiopharm; 2016 Feb 16; 31(1):20-8. PubMed ID: 26844849
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.